Literature DB >> 27170148

Impact of Oversizing on the Risk of Retrograde Dissection After TEVAR for Acute and Chronic Type B Dissection.

Lei Liu1, Simeng Zhang1, Qingsheng Lu2, Zaiping Jing1, Suming Zhang1, Bing Xu3.   

Abstract

PURPOSE: To find a suitable rate of thoracic stent-graft oversizing by exploring its association with the occurrence of retrograde type A dissection (RTAD) after thoracic endovascular aortic repair (TEVAR) for type B aortic dissection.
METHODS: From January 2013 to June 2014, 203 patients (mean age 55 years; 167 men) with type B aortic dissection underwent TEVAR. The mean rate of oversizing at the proximal landing zone was 10% (range 0%-32%). Patients were stratified into 2 groups based on the degree of oversizing: ≤5% (n=105, mean 1.2%±1.5%) and >5% (n=98, mean 18.5%±2.8%). TEVAR-related complications, including RTAD, stent migration, and type I endoleaks, were analyzed.
RESULTS: There were no significant differences in the preoperative proximal landing zone diameters between the groups (31.1 mm for the ≤5% group vs 31.8 mm for the >5% group, p=0.229). The incidence of type I endoleaks over a mean follow-up 15.1±6.4 months was 5.4% [6 (5.7%) in the ≤5% group vs 5 (5.1%) in the >5% group, p=0.847]. The stent migration rate was low in both groups (1% vs 2%, respectively; p=0.521). The occurrence of RTAD [0 in the ≤5% group vs 11 (11.2%) in the >5% group] was significantly associated with the rate of oversizing (p<0.001).
CONCLUSION: The early and midterm outcomes of this study demonstrate that ≤5% oversizing may be a suitable option for thoracic endografts used to treat type B dissection. The smaller rate of oversizing can lower the incidence of RTAD without increasing stent migration or type I endoleak rates.
© The Author(s) 2016.

Entities:  

Keywords:  Stanford type B aortic dissection; aortic dissection; endoleak; migration; retrograde aortic dissection; stent-graft oversizing; thoracic endovascular aortic repair; type I endoleak

Mesh:

Year:  2016        PMID: 27170148     DOI: 10.1177/1526602816647939

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  6 in total

1.  Endovascular ascending aortic repair in type A dissection: A systematic review.

Authors:  Yunus Ahmed; Ignas B Houben; C Alberto Figueroa; Nicholas S Burris; David M Williams; Frans L Moll; Himanshu J Patel; Joost A van Herwaarden
Journal:  J Card Surg       Date:  2020-11-10       Impact factor: 1.620

2.  Virtual stenting with simplex mesh and mechanical contact analysis for real-time planning of thoracic endovascular aortic repair.

Authors:  Duanduan Chen; Jianyong Wei; Yiming Deng; Huanming Xu; Zhenfeng Li; Haoye Meng; Xiaofeng Han; Yonghao Wang; Jia Wan; Tianyi Yan; Jiang Xiong; Xiaoying Tang
Journal:  Theranostics       Date:  2018-11-10       Impact factor: 11.556

3.  A graft inversion technique for retrograde type A aortic dissection after thoracic endovascular repair for type B aortic dissection.

Authors:  Wenbin Hu; Yiran Zhang; Lei Guo; Jingya Fan; Yuan Lu; Liang Ma
Journal:  J Cardiothorac Surg       Date:  2019-02-04       Impact factor: 1.637

4.  Mid-Term Results of Thoracic Endovascular Aortic Repair for Complicated Acute Type B Aortic Dissection at a Single Center.

Authors:  Young Kwang Hong; Won Ho Chang; Dong Erk Goo; Hong Chul Oh; Young Woo Park
Journal:  J Chest Surg       Date:  2021-06-05

5.  Influence of measurement and sizing techniques in thoracic endovascular aortic repair on outcome in acute complicated type B aortic dissections.

Authors:  Miriam Rychla; Philip Dueppers; Lorenz Meuli; Zoran Rancic; Anna-Leonie Menges; Reinhard Kopp; Alexander Zimmermann; Benedikt Reutersberg
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-03-31

6.  Surgical Repair of Two Kinds of Type A Aortic Dissection After Thoracic Endovascular Aortic Repair.

Authors:  Zhou Fang; Haiyang Li; Thomas M Warburton; Junming Zhu; Yongmin Liu; Lizhong Sun; Wenjian Jiang; Hongjia Zhang
Journal:  Front Cardiovasc Med       Date:  2022-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.